Investor Announcements - 2011

EKF wins IMSS contract

30^th Nov 2011

EKF Diagnostics has been awarded a contract in Mexico for 3,500 HemoPoint H2 haemoglobin testing devices.

Announcement of Interim Results

28^th Sep 2011

EKF Diagnostics Holdings plc announces its unaudited interim results for the six month period ended 30 June 2011, a period of transition, investment and progression.

Distribution agreement with Alere

23^rd May 2011

EKF Diagnostics announces that it has entered into a conditional distribution agreement with Alere Inc.

EKF announces acquisition of Stanbio Laboratory

23^rd May 2011

Proposed acquisition of the entire issued share capital of Stanbio Laboratory L.P.

Quotient Diagnostics receives SFDA approval

27^th Jan 2011

Quotient Diagnostics has received approval from China’s SFDA for its Quo-Test A1C test.

Archive

Mount Sinai investments related
RNS announcements

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.